Giles FJ - Search Results

1

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG. Graux C, et al. Among authors: giles fj. Leuk Res. 2013 Sep;37(9):1100-6. doi: 10.1016/j.leukres.2013.04.025. Epub 2013 Jun 5. Leuk Res. 2013. PMID: 23746966 Clinical Trial.

2

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Yee KW, et al. Among authors: giles fj. Leuk Res. 2006 Jul;30(7):813-22. doi: 10.1016/j.leukres.2005.12.013. Epub 2006 Feb 14. Leuk Res. 2006. PMID: 16478631 Clinical Trial.

3

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ. Roboz GJ, et al. Among authors: giles fj. Leukemia. 2006 Jun;20(6):952-7. doi: 10.1038/sj.leu.2404213. Leukemia. 2006. PMID: 16617323 Clinical Trial.

4

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. Giles FJ, et al. Leuk Res. 2007 Jul;31(7):891-7. doi: 10.1016/j.leukres.2006.12.001. Leuk Res. 2007. PMID: 17560285 Clinical Trial.

5

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.

Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Jilani I, et al. Among authors: giles fj. Leuk Res. 2008 Apr;32(4):643-9. doi: 10.1016/j.leukres.2007.08.009. Epub 2007 Sep 27. Leuk Res. 2008. PMID: 17900686

6

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H. le Coutre P, et al. Blood. 2008 Feb 15;111(4):1834-9. doi: 10.1182/blood-2007-04-083196. Epub 2007 Nov 29. Blood. 2008. PMID: 18048643 Free article. Clinical Trial.

7

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.

Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. Jilani I, et al. Leuk Res. 2008 Jun;32(6):936-43. doi: 10.1016/j.leukres.2007.11.023. Epub 2007 Dec 26. Leuk Res. 2008. PMID: 18155764

8

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.

Kelly K, Swords R, Mahalingam D, Giles FJ. Kelly K, et al. Among authors: giles fj. Leuk Lymphoma. 2010 Aug;51(8):1399-413. doi: 10.3109/10428194.2010.491135. Leuk Lymphoma. 2010. PMID: 20528247 Review.

9

Clinical activity of laromustine (Onrigin™) in hematologic malignancies.

Alvarado Y, Swords R, Kelly KR, Giles FJ. Alvarado Y, et al. Among authors: giles fj. Expert Rev Hematol. 2009 Oct;2(5):481-8. doi: 10.1586/ehm.09.38. Expert Rev Hematol. 2009. PMID: 21083013

10

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.

Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. Kelly KR, et al. Among authors: giles fj. J Cell Mol Med. 2011 Oct;15(10):2057-70. doi: 10.1111/j.1582-4934.2010.01218.x. J Cell Mol Med. 2011. PMID: 21091633 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

652 results

Search Page